  | Today's Top Story |  |  | | - Eli Lilly expands collaborative platform
Eli Lilly is expanding its Phenotypic Drug Discovery Initiative to allow scientists from outside the company to have promising molecules tested for free while retaining intellectual property rights. In exchange, the drugmaker get first rights to negotiate a license or collaborative agreement with the scientist. The platform supports molecules for oncology, endocrinology, neuroscience, cardiovascular diseases and multidrug resistant tuberculosis. PharmaTimes (U.K.) (9/29)        | Earn 2X rewards points on gasoline purchases with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, shipping
• 1X points on everything else
• For a limited time, 50K bonus points when you spend $10K your first 5 months
LEARN MORE AND APPLY |
  - NIH-funded team proposes nanomedicine oversight guidelines
A team of experts funded by the NIH released draft guidelines for oversight of human nanomedicine trials. The team suggested creating an interdepartmental working group within HHS to devise a checklist for agencies to use in evaluating the risks of nanoscale experiments. They also recommended creating an HHS advisory committee, and they said that clinical trial participants should be told when nanoscale products are tested on them. Nature News (9/28) - Why targeted therapies need targeted trials
 Targeted therapies that work for specific patient populations should be tested in small, flexible clinical trials instead of large, randomized trials with stringent protocols, according to a study presented at the 2011 European Multidisciplinary Cancer Congress. Small, targeted trials could increase the number of studies researchers are able to conduct, improve patient recruitment efforts and get new therapies to patients faster, says Dr. Marie-Cécile Le Deley, associate professor of clinical epidemiology and biostatistics at the Institut Gustave-Roussy in France. She and her colleagues compared trial designs and found gains in survival with smaller sample sizes, though she conceded that small samples increase uncertainty and are not appropriate for all clinical trials. Medscape (free registration) (9/28) - Study links 3 gene mutations to type 1 diabetes
U.S. researchers analyzed six DNA databases and found that three variations in genes that play a role in protein-protein interactions, cell signaling and inflammation are associated with type 1 diabetes. The findings in the journal PLoS Genetics shed light on genes linked to type 1 diabetes and could pave the way for new treatments, researchers said. HealthDay News (9/29)  | LET’S GO DESIGN: Episode #4
In this episode of SolidWorks’ interactive web series, host Jeremy Luchini starts designing the chassis of the Hot Rod Baby Buggy using weldment features and sketch techniques. He also visits a metal fabrication shop to learn about methods that will help in building our project. Watch the new episode now at LetsGoDesign.tv |
 - Phase II of knockout mouse program gets $110 million from NIH
The University of California, Davis, Baylor College of Medicine and the Jackson Laboratory have received $110 million in funding to work on the second phase of the Knockout Mouse Phenotyping Project over five years. The three institutions will collaborate with the International Knockout Mouse Phenotyping Consortium to develop about 5,000 strains of knockout mice, which could one day help them pinpoint genes that are responsible for causing diseases and determine pharmaceutical targets. GenomeWeb Daily News (9/29) - Proximagen will sell minority stake to Lundbeck for $16M
H. Lundbeck will purchase $16.1 million in shares, or a 9% stake, of Proximagen Group as part of a deal to co-develop therapies for disorders of the central nervous system. The partnership will give Lundbeck negotiation rights to three research programs at Proximagen. Reuters (9/29) - U. of Pennsylvania's Perelman School of Medicine labs get NIH grants
The NIH has awarded a total of $12.5 million in grants to three laboratories at the University of Pennsylvania Perelman School of Medicine. Among the recipients are the researchers at the F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute. They plan to use a five-year, $4 million grant to develop drugs for inherited forms of blindness using light-sensitive molecules. MedCityNews.com (9/29)  | FREE TRIAL – Thomson Reuters Cortellis™ Pipeline Intelligence
Discover new opportunities in drug development and licensing faster. Cortellis gives you an innovative way of finding and acting on drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented.
Click here to see if you qualify for a free trial! |
| Industrial & Environmental | |  | | |  | - Amyris shows interest in Renmatix's biomass-to-sugar pathway
Amyris is interested in a process developed by Renmatix that uses compressed hot water to extract sugars from biomass, said Amyris CEO John Melo. Renmatix's process does not need chemicals to release the sugars, Melo said. "I like this because it's simple," he added. Bloomberg (9/28)  | How will IM, video, telephony and other elements of UC change in the coming year? This set of products provides a consistent unified user interface and experience and is poised to become more widespread in the enterprise. Get insight from Focus Experts as they share their predictions for Unified Communications in this free guide. |
 | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | If you tell the truth, you have infinite power supporting you; but if not, you have infinite power against you."
--Charles Gordon,
British army officer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, September 29, 2011
- Wednesday, September 28, 2011
- Tuesday, September 27, 2011
- Monday, September 26, 2011
- Friday, September 23, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment